Protection conferred by live infectious bronchitis vaccine viruses against variant Middle East IS/885/00-like and IS/1494/06-like isolates in commercial broiler chicks. by Awad, Faez et al.
Protection conferred by live infectious
bronchitis vaccine viruses against
variant Middle East IS/885/00-like and
IS/1494/06-like isolates in commercial
broiler chicks
Faez Awad,1,2 Anne Forrester,1 Matthew Baylis,1,3 Stephane Lemiere,4
Kannan Ganapathy1
To cite: Awad F, et al.
Protection conferred by live
infectious bronchitis vaccine
viruses against variant Middle
East IS/885/00-like and IS/
1494/06-like isolates in
commercial broiler chicks.
Vet Rec Open 2015;2:
e000111. doi:10.1136/
vetreco-2014-000111
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
vetreco-2014-000111).
Received 1 December 2014
Revised 20 May 2015
Accepted 29 June 2015
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
3.0 Licence; see
http://vetreco.bmj.com
For numbered affiliations see
end of article.
Correspondence to
Dr Kannan Ganapathy;
gana@liv.ac.uk
ABSTRACT
The ability of the infectious bronchitis H120
(a Massachusetts strain) and CR88 (a 793B strain) live
attenuated vaccine viruses to protect from two Middle
East infectious bronchitis virus isolates, IS/885/00-like
(IS/885) and IS/1494/06-like (IS/1494) in broiler chicks
was investigated. Day-old chicks were separated into
three groups, (I) vaccinated with H120 at day-old
followed by CR88 at 14 days-old, (II) vaccinated with
H120 and CR88 simultaneously at day-old and again
with CR88 at 14 days-old, (III) control unvaccinated.
At 30 days-old, each of the groups was challenged
with virulent IS/885 or IS/1494. Protection was
evaluated based on the clinical signs, tracheal and
kidney gross lesions and tracheal ciliostasis. Results
showed that administering combined live H120 and
CR88 vaccines simultaneously at day-old followed by
CR88 vaccine at 14 days-old gave more than 80 per
cent tracheal ciliary protection from both of the Middle
East isolates. In addition, this programme conferred
100 per cent protection from clinical signs and tracheal
or kidney lesions. The other vaccination programme,
H120 at day-old followed by CR88 at 14 days-old, the
tracheal ciliary protection conferred were 60 per cent
and 80 per cent from IS/885/00-like and IS/1494/06-
like, respectively.
INTRODUCTION
Infectious bronchitis virus (IBV) is a ubiqui-
tous virus with high mutation, and a large
number of serotypes or genotypes of IBV
strains have been reported worldwide (de Wit
and others 2011). Variant strains emerge due
to changes in the IBV genome through point
mutations, deletions, insertions or RNA
recombination and these variants are often
responsible for IB outbreaks in vaccinated
chicken ﬂocks (Cavanagh and others 1988,
Jia and others 1995, Liu and others 2007).
Many countries have shown that multiple
variant IBV strains are circulating in their
poultry ﬂocks (de Wit and others 2011).
IS/885/00 and IS/1494/06 or those with
high similarities to these strains of IBVs have
been reported throughout the Middle East
and North Africa (Meir and others 2004),
Iraq (Mahmood and others 2011), Egypt
(Abdel-Moneim and others 2012), Turkey
(Kahya and others 2013) and Libya (Awad
and others 2014a). In most cases, severe
respiratory distress and renal lesions with
high mortality were observed in vaccinated
ﬂocks affected by these strains. It appears
that the conventional H120 vaccines alone
do not provide sufﬁcient protection from
these strains (Meir and others 2004, Kahya
and others 2013). However, development of
vaccines against each of these new variants is
not generally an option due to the high cost
and time required for product registration
(Jackwood and others 2003, Bijlenga and
others 2004). Furthermore, it could be a
never-ending race as new variant IBVs are
constantly emerging in major poultry produ-
cing countries. Instead, it has been recom-
mended that protection conferred by
available live IBV vaccines against new var-
iants should be constantly evaluated
(Alvarado and others 2003). Vaccination with
one serotype does not ensure complete pro-
tection from heterologous strains (Cook and
others 1999) but the use of different combi-
nations of live IBV vaccines has been shown
to be able to induce high and broad protec-
tion from challenges with several heterol-
ogous virulent IBV variants (Gelb and others
1991, Cook and others 1999, Cook and
others 2001, Alvarado and others 2003,
Martin and others 2007, Terregino and
others 2008).
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The objective of this study is to evaluate the protection
conferred by available live IBV vaccines when used in a
strategic manner against the two prominent Middle East
variant IBVs that are related to IS/885/00 (Meir and
others 2004) and IS/1494/06 (GenBank Accesion
number: EU780077). In addition to the conventional
vaccination programme (Mass at day-old followed by
variant at 14 days-old), the authors also evaluated
another vaccination programme where the Mass and
variant live vaccines were given simultaneously at day-old
followed by a variant vaccine at 14 days-old. Following
challenge, protection was assessed based on a ciliostasis
assay as recommended by European Pharmacopoeia
(Europe 2007). In addition, clinical signs and gross
lesions were evaluated.
MATERIALS AND METHODS
Chicks
Day-old commercial broiler chicks with IBV maternally
derived antibodies (MDAs) were obtained from a commer-
cial hatchery. The parent ﬂock of these chicks had been
vaccinated with live IBV H120+ D274 vaccines and with an
inactivated IBV M41. Chicks were kept in an isolation unit
at the University of Liverpool. The chicks were reared on
deep litter with water and feed provided ad libitum.
IBV vaccines
Two different commercial live vaccines were used in this
study; (i) H120, vaccine belonging to Massachusetts sero-
type (Merial S.A.S, Lyon, France) and (ii) CR88, vaccine
belong to 793B serotype (Merial S.A.S, Lyon, France).
The vaccines were kept at 4–8°C until used. Each
vaccine was dissolved in sterile distilled water.
IBV challenge strains
Virulent strains of IBV IS/885/00-like (referred here as
IS/885) and IS/1494/06-like (referred here as IS/1494)
were used as challenge viruses. Both viruses had been
isolated from a recent outbreak of high mortality and
respiratory disease in broiler ﬂocks in Egypt. The isolates
were submitted to the Istituto Zooproﬁlattico
Sperimentale delle Venezie, Padova, Italy as third
passage allantoic ﬂuid. At this laboratory, the allantoic
ﬂuid was screened against avian inﬂuenza virus,
Newcastle disease virus and IBV. It was negative for avian
inﬂuenza virus and Newcastle disease virus but positive
for IBV. At the University of Liverpool, the IS/885 strain
was identiﬁed by reverse transcriptase-PCR and part-S1
sequence analysis showed 90 per cent nucleotide level
identity to the Israeli strain IS/885/00 (Meir and others
2004). Based on part-S1 analysis, the IS/1494 strain
showed 99 per cent nucleotide level identity to the
Israel strain IS/1494/06. A pairwise comparison of the
S1 gene sequences of IS/885/00-like and IS/1494/
06-like showed low level identity to the Mass and 793B
types (Awad and others 2014a). The titre of the isolates
were determined in speciﬁc pathogen-free embryonated
chickens eggs and expressed as 50 per cent egg infec-
tious doses (EID50) following the method of Reed and
Muench (Reed and Muench 1938).
Experimental design
Ninety one-day old commercial broiler chicks were
divided into three groups of 30 chicks and housed in
different isolation rooms. At one day of age, Group I was
inoculated with H120 vaccine. Group II, was inoculated
with combined H120 and CR88 vaccines. At 14 days of
age, birds in Group I and II were revaccinated with
CR88 vaccine. Group III was sham-inoculated at 1-day
and 14 days old. Each chick was inoculated via oculo
(50 µl)-nasal (50 µl) routes. Dosages were given as
recommended by the manufacturer. Following the vacci-
nations, the birds were observed daily for clinical signs.
Blood was collected prior to vaccination (at 1 day) and
30 days old from eight chicks in each group for antibody
responses. On the same day, 10 chicks from each group
(vaccinated and control groups) were transferred to
another isolation room and challenged by the oculona-
sal route with 0.1 ml of virulent IS/885 to provide 104.66
EID50/chick. Another 10 chicks from each group were
similarly transferred and challenged with 0.1 ml of viru-
lent IS/1494 to provide 105.00 EID50/chick. The remain-
ing 10 chicks (vaccinated or unvaccinated control) in
each group were left as unchallenged controls. The
birds were observed daily for clinical signs during the
postchallenge period. Five days after challenge, all ten
chicks in each unchallenged and challenged group were
humanely euthanased by wing vein injection of 0.5–1 ml
of Euthenal (pentobarbitone sodium, Rhone Merrieux,
Ireland). Vaccine protection was evaluated by a ciliostasis
test and examination of trachea and kidneys for gross
lesions.
Detection of antibody responses
Sera collected prior to vaccination and 30 days old were
tested using commercial ELISA (BioChek, Gouda, the
Netherlands) following the protocols recommended by
the manufacturer. The haemagglutination inhibition
(HI) test was carried out as described before (Alexander
and Chettle 1977). The IBV antigens used for the HI
assay were M41 and 793B which were purchased from
Animal Health Service, Deventer, The Netherlands. The
haemagglutinin antigens of IS/885 and IS/1494 were
prepared in the authors’ laboratory based on the
method described before (Alexander and Chettle 1977,
King and Hopkins 1983).
Ciliostasis test
Assessment of protection from the challenge viruses
were carried out as described by others (Cook and
others 1999). Five days after challenge, birds were
humanely killed, a section of trachea (immediately after
larynx to thoracic inlet) was carefully dissected out and
placed into warm (37°C) tracheal organ culture medium
(Eagle’s serum-free minimum essential medium with
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glutamine and streptomycin (50 mg/ml) and penicillin
(50 iu/ml)). The trachea was cut using a tissue chopper
(The Mickle Laboratory Engineering) to give 6 µm
thickness of rings, and rings of three from the top and
bottom, and four from the middle trachea were exam-
ined for ciliary activity using a low-power microscope
(×100 magniﬁcation). For each of the rings, the ciliary
activity was scored; 0, all cilia beating; 1, 75 per cent
beating; 2, 50 per cent beating; 3, 25 per cent beating;
and 4, none beating (100 per cent ciliostasis). For each
bird, out of the 10 rings examined, the maximum pos-
sible ciliary score is 40, which indicates a total lack of
protection (no cilia beating in all 10 rings). The mean
ciliary scores for each bird was calculated and percent-
age protection for each group using a formula described
by others (Cook and others 1999); [1−(mean ciliostasis
score for vaccinated/challenge group)/mean ciliostasis
score for corresponding challenge controls)]×100.
Gross lesions
All chicks that were euthanased at ﬁve day post chal-
lenge (dpc) were also examined individually for gross
tracheal and kidney lesions and scored accordingly
using a four-point scale. For the trachea, 0=no lesions,
1=congestion, 2=mucoid exudate in the trachea and
bronchi, 3=caseous exudate plug in the trachea and
bronchi, air sacculitis, perihepatitis and pericarditis, (ii).
For kidneys, 0=no lesions, 1=swollen and pale, 2=swollen
with visible urates, 3=large swelling, pale with tubules
and ureters distended with urates. Total gross lesions
scores for each group were calculated based on the
mean of scores observed per total number of chicks.
Statistical analysis
The ELISA, HI antibody titres and gross lesions between
groups were analysed statistically using analysis of vari-
ance followed by Tukey’s test for comparison of means.
Differences were considered to be signiﬁcant when
P≤0.05. All analyses were conducted using the
GraphPad Prism software, V.6.0.1.
RESULTS
Clinical signs post vaccination
There were no clinical signs found in the unvaccinated
control chicks. In both vaccinated groups, mild clinical
respiratory signs began to appear at six days post vaccin-
ation (dpv). The signs included head shaking, tracheal
râles and sneezes. These signs subsided by 12 dpv.
Serology
The mean ELISA antibody titre prior to vaccination (at
day-old, MDA) was 4174±636. The means of IBV HI
titres against IBV M41, 793B, IS/885 and IS/1494 prior
to vaccination (at day-old, MDA) were log2 6.3, log2 5.6,
log2 3.5 and log2 3.1, respectively.
At 30 days of age (on the day of challenge), vaccinated
groups showed signiﬁcantly higher levels of IBV ELISA
antibody titre than the unvaccinated control group.
Chicks of group II (d0:H120+CR88, d14:CR88) exhib-
ited signiﬁcantly higher antibody titre (P<0.05) than
group I (d0:H120, d14:CR88) (Fig 1). The HI response
to M41 and 793B were higher than the heterologous
antigens (IS/885 and IS/1494) (Fig 2). Using the M41
as antigen, the vaccinated chickens showed high level of
HI antibody titre compared with the control group
(Group III). The antibody titre against 793B antigen in
group II was signiﬁcantly higher than group I (Fig 2).
Clinical signs post challenge
The unvaccinated and vaccinated-unchallenged groups
remained free of clinical signs. All the 10 chicks of
unvaccinated-challenged chicks showed signs of typical
IBV infection at 1 dpc which including depression with
rufﬂed feathers, listlessness and huddling, head shaking,
tracheal râles, sneezing and coughing. These signs were
continued up to 5 dpc. In contrast, no clinical signs
were observed in both of the vaccinated-challenged
groups.
Tracheal ciliary assessment
The percentage ciliary protection was calculated for each
group. The unvaccinated and vaccinated-unchallenged
groups had greater than 98 per cent protection. The
unvaccinated (group III) birds challenged with either
IS/885 or IS/1494 viruses had 0 per cent protection
(Table 1). Group II (d0:H120+CR88, d14:CR88) and
group I (d0:H120, d14:CR88) showed 83 per cent and 60
per cent ciliary protection from IS/885 challenge,
respectively (Table 1). Following challenge with IS/1494,
group I and group II gave 80 per cent and 94 per cent
protection, respectively (Table 1).
Gross lesions
The unvaccinated and vaccinated-unchallenged control
groups remained free of gross lesions. Five days after the
IS/885 challenge, congestion of the trachea and pale
swollen kidneys were observed in all chicks in group III
(unvaccinated-challenged), which were signiﬁcantly dif-
ferent from vaccinated groups (P=0.02). These lesions
were also found in group I (Table 1). However, no sig-
niﬁcant difference was observed between group I and
group III regarding kidney lesions (P=0.06). Birds in
group II were free of these gross lesions. Following the
IS/1494 challenge, congestion of trachea and pale
swollen kidney was observed in one bird in group I,
while it appeared normal in the rest of the birds
(Table 1). Chicks in group II showed no tracheal or
kidney lesions. However, no signiﬁcant difference was
observed between the two vaccinated groups.
DISCUSSION
The evaluation of protection conferred by live vaccines
against the virulent IS/885 and IS/1494 isolates was
assessed based on ciliary activity in the tracheal explants
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prepared from vaccinated-challenged chicks (Darbyshire
1980, Andrade and others 1982, Marquardt and others
1982, Snyder and others 1983, Cook and others 1999)
and gross lesions in the trachea and kidneys following
the challenge with the respective viruses. In this study,
similar to other experimental work (Martin and others
2007, Terregino and others 2008) and ﬁeld practices,
the live vaccines were reconstituted and applied to
chicks at dosages recommended by the vaccine manufac-
turers. The combined vaccination programme where
both live H120 and CR88 vaccines were simultaneously
given at one day-old followed by CR88 vaccine two weeks
later (Group II) provided an excellent protection from
both isolates. Following the challenges, there were no
clinical signs or tracheal/kidney lesions and the ciliary
protection was high (83–94 per cent).
Group 1, which had live H120 vaccine alone at day-old
followed by CR88 vaccine two weeks later showed 60 per
cent and 80 per cent protection from IS/885 and IS/
1494/06-like, respectively. It appears that the protection
conferred was much improved when the CR88 was given
together (Group II) with the H120 at day-old in contrast
to H120 given alone (Group 1). It must be noted that
the vaccine programme given to group II also offered
100 per cent kidney protection from both isolates. In a
previous study performed in speciﬁc pathogen-free
chicks, live H120 vaccination afforded protection of the
trachea (92 per cent) and the kidney (25 per cent) on
the basis of virus isolation when the birds were chal-
lenged with IS/885/00 (Meir and others 2004).
Moreover, immunisation with live H120, H52 and D274
given singly was reported to produce little cross-
protection from challenge with other nephropathogenic
IBV strains (Albassam and others 1986, Lambrechts and
others 1993, Pensaert and Lambrechts 1994). The
present study shows that the vaccination programme of
group II has further boosted the ciliary and tracheal/
kidney protection from IS/885 compared with that of
group I.
Both vaccination programmes used in this experiment
provided excellent protection from the virulent IS/1494
challenge. A better protection observed in group II (d0:
FIG 1: Mean ELISA antibody titres at 30 days of age. Group I=d0:H120, d14:CR88; group II=d0:H120+CR88, d14:CR88; group;
III=control. Bars represent the mean±SD for eight birds in each group. Different superscript lowercase letters in the bar indicate
significant difference (P<0.05), while data with same letters indicate that there were no significant differences (P>0.05). The
cut-off titre=834
FIG 2: Haemagglutination inhibition (HI) antibody titres log2 against infectious bronchitis virus (IBV) antigens at 30 days of age.
Group I=d0:H120, d14:CR88; group II=d0:H120+CR88, d14:CR88; group III= control. Bars represent the mean±SD for eight
birds in each group. Different superscript letters in the bar indicate significant difference (P<0.05), while data with same letters
indicate that there were no significant differences (P>0.05) (within same antigen). The cut-off titre=3log2
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H120+CR88, d14:CR88) as compared with group I (d0:
H120, d14:CR88), could be due to the higher levels of
local and cellular immunity at the tracheal site which
may have prevented the virulent virus from reaching the
kidneys (Lambrechts and others 1993). In an another
experiment, cellular and local immunity induced by
administration of combined live Massachusetts and
793B-type vaccines at day-old showed a signiﬁcant
increase in the expression of CD4+, CD8+ and
IgA-bearing B cells in the trachea compared with single
H120 alone or unvaccinated groups (Awad and
Ganapathy, unpublished). These results reinforce the
importance of optimising local and cell-mediated
mucosal immunity at the respiratory lining through stra-
tegic heterologous day-old vaccination for enhanced pro-
tection from variant viruses.
Humoral antibody responses following vaccination as
measured by ELISA and HI are often used for monitor-
ing vaccine-take (Raj and Jones 1997). In this study, at
30 days of age (challenge day) the mean ELISA titre and
the mean 793B HI titre in group II were signiﬁcantly
higher than the other vaccinated group. This reﬂects
that combined live IBV vaccination at day-old and revac-
cination at 14 days-old has provided an immunological
boost compared with the other vaccination schedule
(group 1). Although it has been demonstrated before
that circulating humoral antibody levels are of minor
importance in the protection from IBV infection (Raggi
and Lee 1965, Darbyshire and Peters 1985, Endo-Munoz
and Faragher 1989, Pensaert and Lambrechts 1994), in
the present study the group with higher levels of
humoral antibodies had better protection from both of
the Middle East isolates. Cytotoxic T cell plays a vital
anti-viral activity during early stages of IBV infection
while serum IgG is critical at the late stage of IBV infec-
tion (Collisson and others 2000).
Despite the low level of genetic identity in the S1
protein between the vaccine and challenge strains used
in this study, the protection achieved with the vaccin-
ation programme employed in the present study was
high. The genetic relationship of the hypervariable
region of the S1 gene between IS/885 and H120 or
CR88 was 80 per cent and 79 per cent, respectively,
while the genetic relationship between the IS/1494 and
H120 or CR88 was 81 per cent and 80 per cent, respect-
ively (Awad and others 2014a). Despite the 19–21 per
cent variation in the S1 gene, the successful protection
conferred by vaccination programmes employed in this
study may be attributable to the shared characteristics of
the S1 protein of the vaccine and the challenge IBVs
(Cavanagh and others 1986).
Based on the data presented in this study, it appears
that a combination of live H120 and CR88 vaccines
given at day-old followed by CR88 vaccine at day 14 of
age confer an excellent protection from virulent variant
IS/885 and IS/1494 viruses. More work is needed to
establish the underlying immune mechanisms for such
higher and broader protection conferred by this vaccin-
ation programme.
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